Author

R. Brinker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 1

Frequent Co-Authors

D. Vorholt· 3 shared E. Izquierdo· 3 shared M. Hallek· 3 shared M. Michalik· 3 shared N. Nickel· 3 shared C. P. Pallasch· 2 shared M. Koch· 2 shared M. Krueger· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Vorholt

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pentose Phosphate Pathway Inhibition activates Macrophages towards phagocytic Lymphoma Cell Clearance

A. C. Beielstein, E. Izquierdo, S. J. Blakemore, N. Nickel, M. Michalik, S. Chawan, R. Brinker, H.-H. Bartel, D. Vorholt, J. L. Nolte, R. Linke, C. R. Costa Picosi, J. Saiz, F. Picard, J. Meinel, , C. P. Pallasch

This study shows that inhibiting the pentose phosphate pathway enhances macrophage phagocytosis of lymphoma cells and improves survival in a mouse model.

bioRxiv · Jun 9, 2023 · PreprintCancer Biology

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber, C. Rohde, S. Halwe, M. S. Ercanoglu, L. Gieselmann, M. Korenkov, H. Gruell, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, , F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

bioRxiv · Jun 12, 2020Immunology

Loss of TP53 mediates suppression of Macrophage Effector Function via Extracellular Vesicles and PDL1 towards Resistance against Chemoimmunotherapy in B-cell malignancies

E. Izquierdo, D. Vorholt, B. Sackey, J. Nolte, S. J. Blakemore, J. Schmitz, V. Barbarino, N. Nickel, D. Bachurski, L. Lobastova, M. Nikolic, M. Michalik, R. Brinker, R. Neuhaus, L. Frenzel, , C. Pallasch

This paper identifies that TP53 loss in B-cell lymphoma leads to resistance against chemoimmunotherapy by suppressing macrophage effector function through PDL1-expressing extracellular vesicles.

bioRxiv · Jun 11, 2020 · PreprintCell Biology

Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2

V. Barbarino, S. Henschke, S. Blakemore, E. Izquierdo, M. Michalik, R. Brinker, N. Nickel, I. Moellenkotte, D. Vorholt, O. Fedorchenko, N. Mikhael, T. Seeger-Nukpezah, M. Hallek, C. P. Pallasch

The paper shows ibrutinib enhances macrophage-mediated antibody-dependent cellular phagocytosis in B-cell lymphoma by inhibiting JAK2, improving treatment outcomes.

bioRxiv · Jun 10, 2020Cancer Biology